This session provides a concise, evidence-based update on canine haemangiosarcoma, with a strong focus on contemporary treatment strategies. It includes a brief, targeted review of current literature outlining standard-of-care approaches, outcomes, and the limitations of existing therapies.
Anthelmintic resistance is a growing threat to equine welfare, and vets play a key role in driving the behaviour changes needed. This talk reviews the latest evidence and expert consensus on sustainable equine parasite control, highlighting updated risk-based approaches from the BEVA ProtectMeToo Toolkit and CANTER Guidelines. Attendees will leave informed, motivated, and ready to champion responsible deworming – protecting equine health, welfare, and the environment.
In this free webinar, Margie will share practical, real-world approaches to common anaesthetic and analgesic challenges, with a focus on what can be achieved, even when working with limited agents, drugs, or resources in unique clinical settings.
Discover new therapeutic approaches for Feline Chronic Gingivostomatitis, including EIDD-1931, doxycycline, and meloxicam. Join Dr Andrea Harvey.
Explore how relational prescribing can transform veterinary behaviour cases. Join Dr Findy Wills to integrate medication with relationship-centred care.
Join Dr James Oliver, Veterinary Ophthalmologist, for an in-depth look at ocular diseases caused by Feline Herpesvirus-1 (FHV-1). Through detailed clinical images, James will explain how to recognise, diagnose, and manage conditions such as:
Corneal ulceration and conjunctivitis
Symblepharon and corneal sequestrum
Eosinophilic keratitis
Currently available pharmacological OA treatments only improve pain or symptoms and are frequently associated with side effects. There are no approved disease-modifying osteoarthritic drugs (DMOADs) on the market yet. A DMOAD typically must show improvement in joint structure, and slow down the progression of cartilage, bone and synovium destruction, with or without an efficacy on joint pain. Therefore, molecular tools are crucial for diagnosing OA and monitoring intervention efficacy. I will talk about a new drug combination with disease-modifying properties and biomarkers for monitoring the destruction of the joint pre-and post-treatment.
Learn when and how to use antibiotics in veterinary ophthalmology. Join Dr Robin Stanley for a case-based webinar on effective, evidence-based eye care.
